Skip to content
MedsAcross

Medicine

Taclonex 0.5 mg/50 mcg per g topical suspension

Available on requestPrescription onlyUS FDA

Taclonex 0.5 mg/50 mcg per g topical suspension is a prescription medicine containing Betamethasone dipropionate and Calcipotriene for topical use, marketed by LEO Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Do not refrigerate. Store between 20°C - 25°C (68°F - 77°F), excursions…

Key facts

Active ingredient (INN)
Betamethasone dipropionate and Calcipotriene
Brand
Taclonex
Strength
0.5 mg/50 mcg per g
Dosage form
Topical suspension
Route
Topical
Packs
40 cartons, 10 package
Marketing authorisation holder
LEO Pharma
Manufacturer
LEO Pharma
Origin register
US FDA, United States
Storage
Do not refrigerate. Store between 20°C - 25°C (68°F - 77°F), excursions permitted between 15°C - 30°C (59°F - 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 June 2008
Identifiers
RxCUI 833461, 833463DailyMed set ID 757c914f-dd8d-43cc-a973-212d591af4afNDC 50222-501Application NDA022185

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
40 carton in 1 case / 1 bottle in 1 carton / 60 g in 1 bottle50222-501-06LEO Pharma1 June 2008
10 package in 1 box / 2 bottle in 1 package / 60 g in 1 bottle50222-501-66LEO Pharma1 June 2008

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 9 January 2006Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspension.

Compare 1

Other strengths and forms of Betamethasone dipropionate and Calcipotriene

Clinical summary

Betamethasone dipropionate and Calcipotriene is a fixed-dose combination of a corticosteroid and a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. MedsAcross supplies Betamethasone dipropionate and Calcipotriene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Betamethasone dipropionate and Calcipotriene

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Taclonex 0.5 mg/50 mcg per g topical suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.